Decreased serum apolipoprotein AII/AI ratio in systemic amyloidosis
- Toshiyuki Yamadaa,
- Tetsuo Ozawab,
- Fumitake Gejyoc,
- Yasuaki Okudad,
- Kiyoshi Takasugid,
- Osamu Hottae,
- Yoshihisa Itoha
- aDepartment of Clinical Pathology, Jichi Medical School, Tochigi, Japan, bDepartment of Clinical Laboratory Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan, cDepartment of Laboratory and Clinical Medicine, Fukui Medical School, Fukui , Japan, dCentre for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Japan, eDepartment of Nephrology, Sendai Shakaihoken Hospital, Sendai, Japan
- Dr T Yamada, Department of Clinical Pathology, Yakushiji, Minamikawachi, Tochigi 329–04, Japan.
- Accepted 27 February 1998
Abstract
OBJECTIVE To investigate if serum apolipoprotein A-I and A-II (apoAI and apoAII) concentrations change in subjects with systemic amyloidosis secondary to underlying disorders.
METHODS Serum concentrations of apoAI and apoAII were measured in 21 multiple myeloma patients, including eight with amyloidosis; 95 rheumatoid arthritis patients, including 45 with amyloidosis; and 73 haemodialysis patients, including 32 with amyloidosis.
RESULTS ApoAII values tended to be reduced in subjects with amyloidosis in each group, but could not effectively distinguish amyloidosis. However, apoAII/AI ratios were significantly lower in subjects with amyloidosis in all groups. The ratio of 0.2 had diagnostic sensitivity and specificity for amyloidosis; 50% and 100%, respectively, in multiple myeloma; 80% and 78%, respectively, in rheumatoid arthritis; and 46% and 90%, respectively, in patients requiring long term haemodialysis.
CONCLUSION The apoAII/AI ratio can be a useful biochemical marker of suspect amyloidosis in patients with underlying diseases, especially those with rheumatoid arthritis.
